ANXA5 and lip and oral cavity carcinoma: Inhibits cell proliferation; apoptosis in OSCC cells, as evidenced by an increased percentage of cells in the sub-G1 phase of the cell cycle, annexin V-positive/propidium iodide-negative cells, and nuclear morphology; new chemotherapeutic agent targeting NF-κb and PIN1 in oral cancer [240].